Results 41 to 50 of about 6,345 (201)

Efficacy of Low-dose Naltrexone Compared to Gabapentinoids in Fibromyalgia [PDF]

open access: yes
• . This literature review evaluates the efficacy, safety, and tolerability of low-dose naltrexone (LDN) compared to gabapentinoids, including gabapentin and pregabalin, in the management of fibromyalgia symptoms.
Boen, Dillon
core   +4 more sources

Gabapentinoid Benefit and Risk Stratification: Mechanisms Over Myth

open access: yesPain and Therapy, 2020
Introduction Recent years have seen a dramatic escalation of off-label prescribing for gabapentin and pregabalin (gabapentinoids) owing in part to generic versions of each being released over the past two decades, but also in part as a response to ...
Heath McAnally, Udo Bonnet, Alan D. Kaye
doaj   +1 more source

The effect of opioid analgesics, benzodiazepines, gabapentinoids, and opioid agonist treatment on mortality risk among opioid-dependent people.

open access: yesInternational Journal of Population Data Science, 2022
Background As dispensings for benzodiazepines and gabapentinoids have increased in recent years, risk of increased mortality has been identified, particularly when used with opioids. There is limited research examining use of these medicines among people
Chrianna Bharat   +6 more
doaj   +1 more source

Gabapentin as an add‐on analgesic to morphine in paediatric patients with chronic pain

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Off‐label use of gabapentin for the treatment of chronic pain in children has increased over the last decade, with multiple clinical trials evaluating its role pain management and potential opioid‐sparing effects. To date, however, these studies appear to rely on empirical evidence without further consideration of pharmacokinetic‐pharmacodynamic ...
Paul Healy   +15 more
wiley   +1 more source

Gabapentinoïdes : mésusages et addictions [Gabapentinoids : misuses and addictions]

open access: yes, 2021
Cases of addictions and misuses on gabapentinoids are increasingly reported. But the underlying pharmacological mechanism is not completely understood.
Vandenberghe, F.   +7 more
core   +1 more source

Translational development of crisugabalin for neuropathic pain

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Crisugabalin (HSK16149) is a next‐generation α2δ ligand developed to preserve the mechanistic rationale of gabapentinoids while refining target engagement and exposure‐related tolerability constraints. We performed a translational review of molecular/structural studies, in vivo pharmacology and behavioural safety assessments, phase I clinical ...
Rafael Batista João   +5 more
wiley   +1 more source

Gabapentinoids: A review of the literature

open access: yes, 2021
The objective of this review is to produce a synthesis of the state of knowledge regarding the epidemiology, pharmacology, clinical and analytical toxicology of gabapentinoids. The pharmacological class of gabapentinoids is mainly represented by gabapentin and pregabalin, which were marketed around the 2000s. Soon after their marketing, cases of misuse
Bargel, Sophie   +7 more
openaire   +1 more source

Diabetic painful polyneuropathy treatment [PDF]

open access: yesSerbian Journal of Anesthesia and Intensive Therapy, 2017
Diabetic peripheral neuropathies (DPN) are a heterogeneous group of disorders caused by neuronal dysfunction in patients with diabetes. Among all acquired polyneuropathy, diabetic polyneuropathy is the most common, and therefore the most important one ...
Terzić Branka
doaj   +1 more source

Benzodiazepines use in primary care England: Prescribing patterns and adverse consequences

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Benzodiazepines (BZDs) are commonly prescribed for anxiety and insomnia but carry risks such as dependence, adverse drug reactions (ADRs) and mortality. Despite deprescribing efforts, the influence of recent prescribing trends, COVID‐19 and adverse outcomes on prescribing patterns in England remains uncertain.
Alvina Chaudhry   +3 more
wiley   +1 more source

Tramadol Co‐Administration with Oxycodone or Hydrocodone Increases Opioid Burden without Improving Postoperative Pain Control

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Tramadol is frequently co‐prescribed with oxycodone or hydrocodone after surgery under the assumption that its dual mechanism of action provides an opioid‐sparing benefit. However, evidence supporting this practice is limited and inconsistent. We conducted a secondary analysis of the multicenter IGNITE ADOPT‐PGx pragmatic trial of patients undergoing ...
Noor A. Nahid   +302 more
wiley   +1 more source

Home - About - Disclaimer - Privacy